AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01953185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The manual diaphragm release technique
Description: To perform the technique the volunteer was placed in supine position with limbs relaxed. Positioned behind the head of the volunteer, the therapist performed manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib, and guiding forearms toward the shoulders of the corresponding side. In the inspiratory phase, the therapist gently pulled the points of contact with both hands, in the direction of the head, yet slightly lateral, accompanying the elevation movement of the ribs. During exhalation, the therapist deepened contact toward the inner costal, maintaining resistance throughout the inspiratory phase. In the breaths following, the therapist sought to gain traction and smooth increase in the deepening of contacts. This maneuver was performed in two sets of ten deep breaths, with a one minute interval between them.
Study NCT04185857 — intervention group
Intervention type: DRUG
Intervention: canrenone 50-100 mg orally once a day
Description: After two biochemical and clinical evaluations under baseline conditions and after pharmacological washout from diuretics, betablockers, ARBs or ACEI (about 4 weeks) and MRAs (abut 6 weeks), PA patients will be treated with canrenone 50-100 mg orally once a day. After 1 or 2 weeks the dose will be doubled if necessary to control BP and serum potassium.
Study NCT04185857 — intervention group
Intervention type: DRUG
Intervention: olmesartan 10-20 mg orally once a day
Description: After one month of treatment with canrenone the patients will undergo a clinical and biochemical evaluation (FW1) in a manner identical to the two basal evaluations. After, they will continue with a combination therapy with canrenone, at the dose reached, plus olmesartan starting with 10 mg a day for oral administration, a dose that could be doubled, if necessary, to achieve normotension.~At the end of the second month of the double therapy, patients will undergo a biochemical re-evaluation at the Center of Hypertension (FW2) with methods identical to those performed in the two baseline evaluations and after one month of canrenone.
Study NCT04182126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular long-lasting insecticidal nets
Description: Olyset nets: containing 2% permethrin or PermaNet 2.0 containing 1.8 and 1.4 g/kg, respectively, for 75 and 100 denier yarn
Study NCT04182126 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Regular long-lasting insecticidal nets
Description: Olyset nets: containing 2% permethrin or PermaNet 2.0 containing 1.8 and 1.4 g/kg, respectively, for 75 and 100 denier yarn
Study NCT04182126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LLIN plus Piperonyl butoxide-treated LLIN
Description: Olyset Plus: containing 2% permethrin and 1% PBO
Study NCT04182126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long-lasting microbial larvicide
Description: Semi-permanent and permanent habitats will be treated with FourStar® 180-day Briquets using the recommended dosage of 100 ft2 water surface per briquet
Study NCT04182126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indoor residual spraying with micro-encapsulated pirimiphos-methyl or other insecticides
Description: Each dwelling's interior walls and ceilings will be sprayed with micro-encapsulated pirimiphos-methyl at the recommended dosage of 1g/m² and at the recommended frequency of once a year or twice a year. Other insecticides may be used to replace the Actellic 300 CS depends on Kenya government policy, current policy requires rotating different insecticides annually.
Study NCT02940457 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verum tDCS
Description: Neuropsychological (working memory) training for 30 minutes, 6 sessions tDCS during training with 2 mA
Study NCT02940457 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tDCS
Description: Neuropsychological (working memory) training for 30 minutes, 6 sessions tDCS during training with 0 mA
Study NCT04490954 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: brain biological electrical impedance tomography
Description: Patients diagnosed with brain supratentorial tumors through MRI/CT are evaluated with brain biological electrical impedance tomography. And the brain biological electrical impedance tomography is used to monitor the cerebral edema situation of patients with brain edema
Study NCT04490954 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRI/CT
Description: Patients diagnosed with brain supratentorial tumors through MRI/CT
Study NCT03414918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Hypertensive patients will be exposed to a single oral dose of 150 mg of roxithromycin. A 150-mg oral dose of roxithromycin should yield peak plasma concentrations of 5-12 mcg/mL14, which are higher than the IC50 measured in vitro (0.18-0.53 mcg/mL).
Study NCT00477373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: depakine chrono
Description: Depakine Chrono 500 mg
Study NCT04565561 — intervention group
Intervention type: DEVICE
Intervention: Neovas BRS or DCB
Description: All STEMI patients were predilated (including predilated balloon or cutting balloon) before randomization. Thrombus aspiration was determined by the surgeon according to the specific situation.~Sufficient predilation criteria: the following two conditions must be met: A. residual stenosis \< 30%; B. no flow limiting dissection or TIMI grade 2-3.
Study NCT01665781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Study NCT02508714 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orsiro
Description: stents will be implanted in case of significant coronary artery disease
Study NCT02508714 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute Onyx
Description: stents will be implanted in case of significant coronary artery disease based on coronary angiography
Study NCT01907074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholates
Description: Cholates is given intravenously (IV push) and by mouth, once per study visit
Study NCT04438096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg
Description: One 100 mg pill and two placebo pills (QD) will be orally administered for 12 weeks
Study NCT02172612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm 1 Education Session
Description: Those included in the intervention group will undergo an educational session with the study pharmacist and one of the licensed prescribers from Sanders-Brown to discuss recommended changes in their treatment plan. If changes in medications are indicated by the pharmacist-prescriber team, and accepted by the patient, new prescriptions will be provided and a letter will be sent to the primary care physicians detailing the changes made and the rationale behind such changes.
Study NCT02708212 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EGD and colonoscopy
Description: Cold forceps biopsy, cold snare polypectomy, and/or hot snare polypectomy will be performed for stomach and/or colon polyps during EGD and colonoscopy examinations will be performed whenever indicated.
Study NCT04438096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg
Description: Two 100 mg pills and one placebo pill (QD) will be orally administered for 12 weeks
Study NCT04438096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 mg
Description: Three 100 mg pills (QD) will be orally administered for 12 weeks
Study NCT04438096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three placebo pills (QD) will be orally administered for 12 weeks
Study NCT01800344 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA
Study NCT01800344 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultra
Description: Ultra
Study NCT01714973 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ST266
Description: Patients will receive ST266 spray, to half the breast and saline to the other half (blinded) after each of ten consecutive radiation therapy treatments. ST266 and saline will be sprayed onto the breast to deliver 0.01 ml/cm2.
Study NCT01812343 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise test
Study NCT04253704 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: IDL lotion
Description: IDL lotion is water-based (> 80%) with isosorbide di-(linoleate/oleate) (2.0%), caprylic/capric triglycerides (5%), glycerin (3%), glyceryl stearate (2.5%), dimethicone (2.0%), steareth-20 (1.5%), cetyl alcohol (1.0%), and butyrospermum parkii (shea) butter (1.0%).
Study NCT04253704 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Control lotion
Description: Control lotion is water-based (> 80%) with caprylic/capric triglycerides (5%), glycerin (3%), glyceryl stearate (2.5%), dimethicone (2.0%), steareth-20 (1.5%), cetyl alcohol (1.0%), and butyrospermum parkii (shea) butter (1.0%).
Study NCT01898312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Randomised controlled trial of Mifepristone and placebo comparator Triobe
Study NCT01898312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mifepristone
Description: Randomised controlled trial of Mifepristone and placebo comparator Triobe
Study NCT05700240 — intervention group
Intervention type: DEVICE
Intervention: orthokeratology
Description: rigid contact lenses
Study NCT05700240 — intervention group
Intervention type: DEVICE
Intervention: single-vision spectacle correction
Description: simple wear of spectacle
Study NCT01883310 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sham tDCS + TOCT
Description: Anodal transcranial direct current stimulation will be delivered through 2 sponge electrodes (surface area: 25 cm2) soaked in a saline solution. For the cerebellar transcranial direct current stimulation, the anodal electrode will be centered on the right cerebellar cortex, 3 cm lateral to the inion, and the cathodal electrode will be positioned on the right buccinator muscle. Anodal stimulation intensity will be set at 2 mili Ampere and delivered using a rechargeable batteries direct current stimulator.The sham transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 30 s over the right cerebellar position.
Study NCT01883310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real tDCS +TOCT
Description: Anodal transcranial direct current stimulation will be delivered through 2 sponge electrodes (surface area: 25 cm2) soaked in a saline solution. For the cerebellar transcranial direct current stimulation, the anodal electrode will be centered on the right cerebellar cortex, 3 cm lateral to the inion, and the cathodal electrode will be positioned on the right buccinator muscle. Anodal stimulation intensity will be set at 2 mili Ampere and delivered using a rechargeable batteries direct current stimulator.The real transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 15 minutes over the right cerebellar position.
Study NCT01172171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin, N-acetyl-5-methoxytryptamine
Description: The investigators will give the randomized patients 10 ml of 0,1 mg/ml melatonin intracoronarily and 490 ml of 0,1 mg/ml (49 mg) melatonin.
Study NCT01172171 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline, Natrium chloride
Description: The randomized patients will be given 10 ml of isotonic saline intracoronarily and 490 ml intravenously.
Study NCT00379938 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAI-VP705 (parvovirus B-19 vaccine)
Description: Recombinant human parvovirus B-19 capsids at dose levels: 25 micrograms of VAI-VP705 with and without MF59 adjuvant and 2.5 micrograms with MF59 adjuvant.
Study NCT00379938 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline control
Study NCT00379938 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF-59
Description: Adjuvant
Study NCT00469235 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Avotermin
Description: 10 patients:- 50ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure.~10 Patients:- 200ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure.
Study NCT02596880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: 400 mg, included in a combination pill (Sovodak) with 60 mg daclatasvir
Study NCT02596880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: 60 mg, included in a combination pill (Sovodak) with 400 mg sofosbuvir
Study NCT02596880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 1000 mg/day if \<75 kg, 1200 mg/day for >75 kg. Divided into two daily doses
Study NCT01426386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 999049
Study NCT01007552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Capecitabine and Bevacizumab
Description: Bevacizumab 15 mg/ kg every 3 weeks, starting day 1; Capecitabine 650 mg/m2 bid x 14 days starting day 1, Gemcitabine 1000 mg/m2 days 1 and 8, cycles to be repeated every 21 days.
Study NCT01426386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonal - F
Study NCT00974662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WST11
Description: WST11-mediated VTP will consists of the combination of a single IV administration of WST11 at doses of 5, 7.5 \& 10 mg/kg, using 753 nm laser light at a fixed power of 250 mW/cm and escalating fixed energy dose (200 Joules/cm and 300 Joules/cm) locally delivered to the obstructing tumor through an optical fiber placed, during endoscopy, in the endoscope operating channel with visual control, possibly video-transmission assisted. The fiber illuminating diffusion length is fixed (2 cm).
Study NCT00785746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core
Description: We have devised a series of core strength training exercises that can be easily and safely performed under the supervision of trained staff. The exercises will be individualized depending on the participants' ability and health conditions. The majority, but not all, of exercises will be performed on or with exercise balls of different sizes and shapes, round for more advanced persons and oval for more frail persons.
Study NCT03515980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986231
Description: Intravenous (IV) administration
Study NCT05450861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SF DNA extraction composition
Description: the composition of small fragments of DNA from fish
Study NCT05450861 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the scalp conditioning solution without SF DNA extraction composition
Study NCT03940144 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: the enhanced flow-based hemodynamic parameters of the FloTrac/Vigileo device
Description: Stroke volume variation (SVV)-guided fluid therapy
Study NCT03940144 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the enhanced flow-based hemodynamic parameters of the FloTrac/Vigileo device
Description: Stroke volume variation (SVV)-guided fluid therapy
Study NCT01225406 — intervention group
Intervention type: DRUG
Intervention: Tenofovir
Study NCT04302181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: 6.5cc of Ropivacaine HCl 0.5%, one time into the stellate ganglion
Study NCT00946270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-4047
Description: 0.5 mg capsules daily by mouth day 1 through day 28.
Study NCT00946270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 30 mg by mouth daily during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
Study NCT00946270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-4047
Description: 3.0 mg capsules daily by mouth day 1 through 21.
Study NCT03159442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Powder for inhalation administered via single dose DPI
Study NCT06626971 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ARA290
Description: 4 mg subcutaneous injections of ARA290 over an 84 day period
Study NCT03821974 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wet suction technique
Description: For the wet suction technique, after removing the stylet, the needle was flushed with 2 mL of saline solution to replace the column of air with saline solution. A 10-mL suction syringe, loaded to 5ml negative pressure, was attached in a locked position to the needle after flushing the needle with saline solution. The needle is moved back and forth 20-30 times by applying negative pressure suction within the lesion. Afterwards, the needle is withdrawn from the lesion.
Study NCT03821974 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dry suction technique
Description: For the dry suction technique, after locating by EUS, the stylet was removed from the needle before performing FNA. A 10-mL syringe, loaded to 5ml negative pressure, was attached in a locked position to the needle. Suction was applied after the lesion was punctured. The needle is moved back and forth 20-30 times by applying negative pressure suction within the lesion. Afterwards, the needle is withdrawn from the lesion.
Study NCT02722421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel
Description: Increased dose levonorgestrel implant plus efavirenz-based antiretroviral therapy.
Study NCT02722421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Participants will receive efavirenz-based ART as part of standard of care
Study NCT02672839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGD-6972 Solution
Description: 15 mg of LGD-6972
Study NCT02672839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGD-6972 Capsules
Description: 15 mg LGD-6972
Study NCT01757457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intracoronary administration of an abciximab bolus during primary PCI
Description: Intracoronary administration of an abciximab bolus (reopro 0.25mg/kg) during primary PCI
Study NCT01757457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous administration of an abciximab bolus during primary PCI
Description: Intracoronary administration of an abciximab bolus (reopro 0.25mg/kg) during primary PCI
Study NCT03427840 — intervention group
Intervention type: PROCEDURE
Intervention: Procedure/Surgery: superior hypogastric block
Description: superior hypogastric blockade during surgery
Study NCT02333045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada qd
Description: Truvada 1 tablet PO daily for 7 days
Study NCT02333045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc 300 qd
Description: Maraviroc 300 mg PO daily for 7 days
Study NCT01751646 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 50,000 IU
Description: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT
Study NCT01751646 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3 placebo
Description: Group B: Vitamin D3 placebo orally every four weeks by DOT
Study NCT03224533 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diabetes Outcome
Description: based on self report definition, fasting plasma glucose, and hemoglobin A1c
Study NCT02727725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traminer MRI Sequence
Description: The Traminer MRI sequence will be added to the standard IR Turbo-Flash sequence and last 2-5 minutes.
Study NCT00945191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-1008
Description: CS-1008 intravenous (IV) infusion 10 mg/kg on Day 1 of Cycle 1 and 8 mg/kg once every 3 weeks (1 cycle) for Cycle 2-6
Study NCT00945191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m\^2 IV infusion once every 3 weeks (1 cycle) for 6 cycles
Study NCT00945191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin (target area under the concentration versus time curve of 6.0 mg/mL/min using the Calvert Formula) IV infusion once every 3 weeks (1 cycle) for 6 cycles
Study NCT02405312 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: advance care planning
Description: patient and family meeting with dialysis social worker and nephrologist with discussion of advance care planning and hospice resources
Study NCT02093026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive rituximab 1 gram IV on Days 1 and 15 of each course of retreatment.
Study NCT03035643 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMDS
Description: The device will be implanted during an already planned surgical intervention for aortic dissection repair. The participant will be observed and data gathered during the surgery and routine standard of care follow up visits.